Trial Profile

An Open-Label, Multi-Center, Dose Escalation, Confirmation, and Expansion Phase I Clinical Study to Evaluate the Safety, Tolerability, Efficacy, and Pharmacokinetics of MRG007 (ARR-217) in Participants With Unresectable Locally Advanced or Metastatic Solid Tumors

Status: Recruiting

Phase of Trial: Phase I

Latest Information Update: 23 Mar 2026

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs MRG 007 (Primary)
Indications Colorectal cancer; Gastrointestinal cancer; Pancreatic cancer; Solid tumours
Focus Adverse reactions; Therapeutic Use
Sponsors Lepu Biopharma; Miracogen

05 Mar 2026 According to ArriVent BioPharma media release, the company plans to complete Phase 1 dose escalation and enter into dose optimization for ARR-217 in 2H 2026.
11 Dec 2025 Phase changed from I/II to I.
11 Dec 2025 Planned number of patients changed from 336 to 405.

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com